EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Infectious complications of car T‐cell therapy: A longitudinal risk model

Michael T Czapka iD, Peter A Riedell, Jennifer C Pisano

Transplant Infectious Disease · 2023-11 · 25 (S1)

DOI: 10.1111/tid.14148 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, online erschienen am 11.09.2023. Verfasst von Michael T Czapka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Infectious Disease, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Candidiasis, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CAR T‐cell therapy, where a patient's own T cells are re‐engineered to express a receptor to a target of interest, is becoming an increasingly utilized cancer‐directed therapy. There are significant toxicities that contribute to a novel state of immunocompromise, leading to new patterns of infectious complications that require further detailed study.

Methods

We created a single‐center cohort of adult recipients of CD19‐directed CAR T‐cell therapy and assessed infectious outcomes, supportive care received, toxicities, and markers of immune function up to 2 years following CAR T‐cell therapy. Descriptive statistics were used as appropriate for analysis. We additionally conducted time‐to‐event analysis assessing time‐to‐first infection with either log‐rank testing or Cox regression with univariate analysis, before including significant predictors into a multivariate Cox model of time to infection.

Results

We identified 73 patients who received CD19‐directed CAR T‐cell therapy who predominantly had diffuse large B‐cell lymphoma. Within 30 days of cell infusion, bacterial and Candida infections were the most common, with 64% of infections due to these organisms. Between 30 days and 2 years postinfusion, respiratory viruses and pneumonia were the most frequent infections, with 68% of infections due to these etiologies. Receipt of tocilizumab, development of immune effector cell‐associated neurotoxicity syndrome (ICANS), or lower neutrophil count were associated with quicker onset of infection in a multivariate Cox model. image Conclusions Respiratory viruses remain an important infectious complication of CAR T‐cell therapy following the first year. The model may be a useful tool to identify patients at the highest risk of infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CandidiasisLymphoma, Large B-Cell, DiffuseAdultHumansImmunotherapy, AdoptiveImmunocompromised HostLeukocyte CountNeurotoxicity Syndromes

Stichwörter der Autor:innen

CAR T-cellcellular therapyinfectionmodel

Substanzen

cell-associated neurotoxicity

Autor:innen und Institutionen

  • Department of Medicine, Section of Infectious Disease, University of Chicago, Chicago, Illinois, USA.
  • Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Michael T Czapka

Zitieren

APA

Czapka, M. T., Riedell, P. A., & Pisano, J. C. (2023). Infectious complications of car T‐cell therapy: A longitudinal risk model. Transplant Infectious Disease, 25(S1). https://doi.org/10.1111/tid.14148

Vancouver

Czapka MT, Riedell PA, Pisano JC. Infectious complications of car T‐cell therapy: A longitudinal risk model. Transplant Infectious Disease. 2023;25(S1). doi:10.1111/tid.14148

BibTeX
@article{Czapka2023,
  author = {Czapka, Michael T and Riedell, Peter A and Pisano, Jennifer C},
  title = {Infectious complications of car T‐cell therapy: A longitudinal risk model},
  journal = {Transplant Infectious Disease},
  year = {2023},
  volume = {25},
  number = {S1},
  doi = {10.1111/tid.14148}
}
Kostenlos starten →